Novel Highly Selective LRRK2 Inhibitor

Novel activator of BMP signaling, enhancing osteoblast differentiation, targeting HECT domain of ubiquitin ligase Smurf1, up-regulating the protein level of Smad1/5

Novel activator of BMP signaling, enhancing osteoblast differentiation, targeting HECT domain of ubiquitin ligase Smurf1, up-regulating the protein level of Smad1/5

Metabolite of BML277 which is a selective checkpoint kinase 2 inhibitor

Potent and selective inhibitor of Cdk5/p25, protecting large population of cells against non-A

Novel potent cyclin-dependent kinases (CDK) inhibitor, inducing a strong cell cycle alteration

Novel inhibitor of RNA polymerase I, causing nucleolar stress and showing potent anticancer activity across many tumor types

Novel LRP5/6-sclerostin interaction inhibitor, recovering the downregulated activity of the Wnt/β-catenin signaling pathway by competitive binding to the LRP5/6-sclerostin complex

Novel potent EGFR inhibitor

Dual thromboxane synthase inhibitor and thromboxane receptor antagonist

Original TXA2 modulator, inhibiting the action of thromboxane A2 and 8-iso-prostaglandin F2alpha

Inhibitor of Marburg virus (MARV) growth at noncytotoxic concentrations

Inhibitor of calpain, cathepsin L and cathepsin B

Novel ERK inhibitor, inducing breast cancer cell apoptosis via mitochondrial pathway but independent on Ras/Raf/MEK pathway

Potent 14-3-3 inhibitor

Natural Potent 14-3-3 inhibitor

Natural anti-coronavirus agent

Bradykinin antagonist, causing impressive growth inhibition of lung and prostate tumors, displaying superior in vivo inhibitory effects than convential chemotherapeutic drugs

Novel inhibitor of the expression of anti-apoptotic protein survivin and membrane-bound efflux pump ATP binding cassette B 1 (ABCB1, p-glycoprotein), presumably via signal transducer and activator of transcription 3 (Stat3), inhibiting human prostate canc

Novel effective inhibitor of survivin expression at both the mRNA and protein levels in vitro, significantly reducing survivin in bone metastatic C4-2 tumors

Novel inhibitor of survivin transcription through a signal transducer and activator of transcription 3 (Stat3)-dependent mechanism, inhibiting tissue expression of survivin and inducing apoptosis in C4-2 skeletal tumor

Novel potent and selective bumped kinase inhibitor (BKI) CpCDPK1 IC 50 0.005 µM

Novel potent and selective bumped kinase inhibitor (BKI) CpCDPK1 IC 50 0.0025 µM

Novel Bumped-Kinase Inhibitor (BKI) for Cryptosporidiosis Therapy

Novel Bumped-Kinase Inhibitor (BKI) for Cryptosporidiosis Therapy

Novel potent and selective covalent Pin1 inhibitor

Potent inhibitor of recombinant human and mouse Transglutaminase enzyme activity, mainly TG2 and the close related enzyme TG1

Potent and selective dual inhibitor of MEK5 and ERK5

Novel potent antagonist of RORγt function, displaying an increased selectivity for RORγt over RORα and PPARγ compared to the purely orthosteric and allosteric non-PEG-linked parent compounds

Inactivator of GSTP1>GST P1-1 through the covalent modification of two Cys47 residues per dimer and one Cys101